N-(2-苯氧基乙基)-2-丙胺 | 55247-30-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: N-(2-苯氧基乙基)-2-丙胺
• 中文别名: N-(2-苯氧基乙基)丙-2-胺
• 英文名称: N-(1-methylethyl)-2-phenoxyethanamine
• 英文别名: N-Isopropyl-2-phenoxy-aethylamin；N-(2-Phenoxyethyl)propan-2-amine
• CAS: 55247-30-8
• 化学式: C₁₁H₁₇NO
• mdl: MFCD08691703
• 分子量: 179.262
• InChiKey: WVFGRNGNOVCUFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi

反应信息

• 作为反应物：
  描述：

  N-(2-苯氧基乙基)-2-丙胺 以 乙醚 为溶剂， 生成 Phenyl-N-isopropyl-N-(2-chloroethyl)carbamat
  参考文献：
  名称：

  Banks,R. et al., Journal of the Chemical Society. Perkin transactions I, 1975, p. 1836 - 1840

  摘要：

  DOI：
• 作为产物：
  描述：

  2-苯氧乙基溴 、 异丙胺 生成 N-(2-苯氧基乙基)-2-丙胺
  参考文献：
  名称：

  FR2234293

  摘要：

  公开号：

文献信息

• Diaryl piperidines as CB1 modulators
  申请人：Scott D. Jack

  公开号：US20070203183A1

  公开（公告）日：2007-08-30

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.

  具有通式（I）的一种化合物，或其药学上可接受的盐、溶剂合物或酯，可用于治疗代谢综合征（例如肥胖、腰围、脂质谱和胰岛素敏感性）、神经炎症性疾病、认知障碍、精神病、成瘾行为、胃肠道疾病和心血管疾病等疾病、疾病或症状。
• [EN] 2,4-DIAMINO-1,3,5-TRIAZINE AND 4, 6-DIAMINO-PYRIMIDINE DERIVATIVES AND THEIR USE AS AGGRECANASE INHIBITORS<br/>[FR] DÉRIVÉS DE 2,4-DIAMINO-1,3,5-TRIAZINE ET DE 4,6-DIAMINO-PYRIMIDINE ET LEUR EMPLOI EN TANT QU'INHIBITEURS D'AGGRÉCANASE
  申请人：PRAECIS PHARM INC

  公开号：WO2010085246A1

  公开（公告）日：2010-07-29

  The invention is directed to compounds of formula (I): that modulate, e.g., inhibit, aggrecanase proteolytic activity, which is implicated in joint diseases including osteoarthritis, joint injury, reactive arthritis, acute pyrophosphate arthritis, psoriatic arthritis, and rheumatoid arthritis. The current invention also relates to processes for making the compounds of the invention and to pharmaceutical compositions containing these compounds. The present invention further provides methods of treating diseases associated with aggrecanase activity, e.g., osteoarthritis and other joint diseases, using the compounds of the invention.

  该发明涉及式(I)的化合物，可调节例如抑制聚集素酶蛋白酶活性，该活性与关节疾病有关，包括骨关节炎、关节损伤、反应性关节炎、急性焦磷酸盐性关节炎、银屑病性关节炎和类风湿性关节炎。该发明还涉及制备该发明化合物的方法以及含有这些化合物的药物组合物。本发明进一步提供使用该发明化合物治疗与聚集素酶活性相关的疾病的方法，例如骨关节炎和其他关节疾病。
• Succinic acid amides as P2–P3 replacements for inhibitors of interleukin-1β converting enzyme (ICE or caspase 1)
  作者：Paul Galatsis、Bradley Caprathe、John Gilmore、Anthony Thomas、Kristin Linn、Susan Sheehan、William Harter、Catherine Kostlan、Elizabeth Lunney、Charles Stankovic、John Rubin、Kenneth Brady、Hamish Allen、Robert Talanian

  DOI：10.1016/j.bmcl.2010.07.004

  日期：2010.9

  Succinic acid amides have been found to be effective P2–P3 scaffold replacements for peptidic ICE inhibitors. Heteroarylalkyl fragments occupying the P4 position provided access to compounds with nM affinities. Utilization of an acylal prodrug moiety was required to overcome biopharmaceutical issues which led to the identification of 17f, a potential clinical candidate.

  已发现琥珀酸酰胺是肽ICE抑制剂的有效P2-P3支架替代物。占据P4位置的杂芳基烷基片段提供了对具有nM亲和力的化合物的访问。需要使用酰基前药部分来克服生物药物问题，从而导致鉴定潜在的临床候选药物17f。
• Naphthyridine derivatives having inhibitory activity against hiv integrase
  申请人：Taishi Teruhiko

  公开号：US20090227621A1

  公开（公告）日：2009-09-10

  [Problems to be Solved] To provide a novel compound having antiviral activity, especially inhibitory activity against HIV integrase, a pharmaceutical composition, especially anti-HIV drug, containing the same. [Means to Solve the Problem] A compound of the formula: (wherein: R 1 is optionally substituted aralkyl; R 2 and R 3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R 4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  【需要解决的问题】提供一种具有抗病毒活性，特别是对HIV整合酶具有抑制活性的新型化合物，以及包含该化合物的制药组合物，特别是抗HIV药物。 【解决问题的方法】 化合物的化学式为：（其中：R1是可选取代的芳基甲基；R2和R3分别是氢、可选取代的烷基、可选取代的氨基、可选取代的烯基或可选取代的烷氧基（提供“可选取代”中的每个取代基均为非环状基）；R4是氢、可选取代的羧基、可选取代的甲酰胺基、可选取代的氨基甲酰胺基、可选取代的氨基（在“可选取代的甲酰胺基”、“可选取代的氨基甲酰胺基”和“可选取代的氨基”中，氨基上的取代基可以与相邻的N原子一起形成一个含有可选取代的N原子的杂环环），可选取代的烷基、可选取代的烯基、可选取代的芳基或可选取代的杂环芳基）或其盐。
• ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF
  申请人：Ohno Michihiro

  公开号：US20100016319A1

  公开（公告）日：2010-01-21

  This invention relates to a pharmaceutical comprising as an effective ingredient an arylmethylene urea exemplified by the following formula: or a pharmaceutically acceptable salt thereof. The arylmethylene urea and the pharmaceutically acceptable salts thereof are useful for therapy or prophylaxis of inflammatory bowel disease and overactive bladder.

  本发明涉及一种药物，其有效成分为以下式子所示的芳基亚甲基脲或其药学上可接受的盐： 该芳基亚甲基脲及其药学上可接受的盐可用于治疗或预防炎症性肠病和过度活跃的膀胱。